Alternate routes for drug delivery to the cell interior: Pathways to the Golgi apparatus and endoplasmic reticulum

Advanced Drug Delivery Reviews

Volumn 59, Issue 8, 2007, Pages 782-797

  Tarragó Trani, Maria Teresa ^a   Storrie, Brian ^b  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

A B toxins; Caveolae; Endoplasmic reticulum; Golgi apparatus; Lipid rafts; Lysosomes; Receptor mediated endocytosis; Retrograde trafficking pathway; Shiga Shiga like toxin; Targeted drug delivery

Indexed keywords

ENDOPLASMIC RETICULUM; GOLGI APPARATUS; LIPID RAFTS; LYSOSOMES; RECEPTOR MEDIATED ENDOCYTOSIS; RETROGRADE TRAFFICKING PATHS;

ANTIGENS; CELLS; PH EFFECTS; PROTEINS; TOXIC MATERIALS;

DRUG DELIVERY;

ANTINEOPLASTIC AGENT; BACTERIAL TOXIN; BEVACIZUMAB; CLATHRIN; CONTRAST MEDIUM; COPOLYMER; DACLIZUMAB; DENILEUKIN DIFTITOX; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORESCEIN; FLUORESCENT DYE; FLUORINE 18; GADOLINIUM; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IODINE 125; IRON OXIDE; LIPOSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; N (2 HYDROXYPROPYL)METHACRYLAMIDE; PK2; RADIOISOTOPE; SHIGA TOXIN; TECHNETIUM 99M; THALLIUM 201; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; VEROTOXIN; VEROTOXIN 1;

B CELL LYMPHOMA; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL KILLING; CELL MEMBRANE; CELL SURFACE; CLINICAL TRIAL; COLON CANCER; COMPUTER ASSISTED TOMOGRAPHY; CYTOSOL; CYTOTOXICITY; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG PROTEIN BINDING; DRUG TARGETING; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; ENDOSOME; GOLGI COMPLEX; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HYDROLYSIS; KIDNEY CANCER; LEUKEMIA; LIPID RAFT; LIVER CANCER; LUNG CANCER; NONHUMAN; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

ANIMALS; ANTIGENS, NEOPLASM; BACTERIAL TOXINS; CHOLERA TOXIN; COAT PROTEIN COMPLEX I; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; ENDOSOMES; GOLGI APPARATUS; HUMANS; INTRACELLULAR MEMBRANES; INTRACELLULAR SPACE; LIPOSOMES; LYSOSOMES; PROTEIN BINDING; PROTEIN SORTING SIGNALS; PROTEIN TRANSPORT; SHIGA TOXIN 1; SHIGA TOXINS; TRANS-GOLGI NETWORK; TRIHEXOSYLCERAMIDES;

EID: 34548229482     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2007.06.006     Document Type: Review

References (163)

1. Torchilin V.P. Recent approaches to intracellular delivery of drugs and DNA and organelle targeting. Annu. Rev. Biomed. Eng. 8 (2006) 43-75
2. Johannes L., and Lamaze C. Clathrin-dependent or not: is it still the question?. Traffic 3 (2002) 443-451
3. Mousavi S.A., Malerod L., Berg T., and Kjeken R. Clathrin-dependent endocytosis. Biochem. J. 377 (2004) 1-16
4. Mellman I., and Warren G. The road taken: past and future foundations of membrane traffic. Cell 100 (2000) 99-112
5. Ohno H., Stewart J., Fournier M.C., Bosshart H., Rhee I., Miyatake S., Saito T., Gallusser A., Kirchhausen T., and Bonifacino J.S. Interaction of tyrosine-based sorting signals with clathrin-associated proteins. Science 269 (1995) 1872-1875
6. Simonsen A., Bremnes B., Nordeng T.W., and Bakke O. The leucine-based motif DDQxxLI is recognized both for internalization and basolateral sorting of invariant chain in MDCK cells. Eur. J. Cell Biol. 76 (1998) 25-32
7. Ford M.G., Pearse B.M., Higgins M.K., Vallis Y., Owen D.J., Gibson A., Hopkins C.R., Evans P.R., and MacMahon H.T. Simultaneous binding of PtdIns(4,5)P2 and clathrin by AP180 in the nucleation of clathrin lattices on membranes. Science 291 (2001) 1051-1055
8. Takei K., and Haucke V. Clathrin-mediated endocytosis: membrane factors pull the trigger. Trends Cell Biol. 11 (2001) 385-391
9. Jin A.J., and Nossal R. Topological mechanisms involved in the formation of clathrin-coated vesicles. Biophys. J. 65 (1993) 1523-1537
10. Schmidt A.A. Membrane transport: the making of a vesicle. Nature 419 (2002) 347-349
11. Kozlov M.M. Fission of biological membranes: interplay between dynamin and lipids. Traffic 2 (2001) 51-65
12. Lee E., and De Camilli P. Dynamin at actin tails. Proc. Natl. Acad. Sci. U. S. A. 96 (2002) 161-166
13. Merrifield C.J., Feldman M.E., Wan L., and Almers W. Imaging actin and dynamin recruitment during invagination of single clathrin-coated pits. Nat. Cell Biol. 4 (2002) 691-698
14. Subtil A., Gaidarov I., Kobylarz K., Lampson M.A., Keen J.H., and McGraw T.E. Acute cholesterol depletion inhibits clathrin-coated pit budding. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 6775-6780
15. Rodal S.K., Skeretting G., Garred O., Vilhardt F., van Deurs B., and Sandvig K. Extraction of cholesterol with methyl-beta-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles. Mol. Biol. Cell 10 (1999) 961-974
16. Lamaze C., and Johannes L. Intracellular trafficking of bacterial and plant protein toxins. In: Alouf J.E., and Popoff M.R. (Eds). The Comprehensive Sourcebook of Bacterial Protein Toxins. third edition (2006), Academic Press, Paris 135-153
17. Laude A.J., and Prior I.A. Plasma membrane microdomains: organization, function and trafficking. Mol. Memb. Biol. 21 (2004) 193-205
18. Simons K., and Ikonen E. Functional rafts in cell membranes. Nature 387 (1997) 569-572
19. Foster L.J., De Hoog C.L., and Mann M. Unbiased quantitative proteomics of lipid rafts reveals high specificity for signaling factors. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 5813-5818
20. Simons K., and Toomre D. Lipid rafts and signal transduction. Nat. Rev. Mol. Cell Biol. 1 (2000) 31-39
21. Palade G.E. Fine structure of blood capillaries. J. Appl. Phys. 24 (1953) 1424
22. Yamada E. The fine structure of the gall bladder epithelium of the mouse. J. Biophys. Biochem. Cytol. 1 (1955) 445-458
23. Couet J., Belanger M.M., Roussel E., and Drolet M.C. Cell biology of caveolae and caveolin. Adv. Drug Del. Rev. 49 (2001) 223-235
24. Rothberg K.G., Heuser J.E., Donzell W.C., Ying Y.S., Genney J.R., and Anderson R.G. Caveolin, a protein component of caveolae membrane coats. Cell 68 (1992) 673-678
25. Harder T., and Simons K. Caveolae, DIGs, and the dynamics of sphingolipid-cholesterol microdomains. Curr. Opin. Cell Biol. 9 (1997) 534-542
26. Sharma D.K., Brown J.C., Choudhury A., Peterson T.E., Holicky E., Marks D.L., Simari R., Parton R.G., and Pagano R.E. Selective stimulation of caveolar endocytosis by glycosphingolipids and cholesterol. Mol. Biol. Cell 15 (2004) 3114-3122
27. Shajahan A.N., Timblin B.K., Sandoval R., Tiruppathi C., Malik A.B., and Minshall R.D. Role of Src-induced dynamin-2 phosphorylation in caveolae-mediated endocytosis in endothelial cells. J. Biol. Chem. 279 (2004) 20392-20400
28. Nichols B.J., and Lippincott-Schwartz J. Endocytosis without the clathrin coats. Trends Cell Biol. 13 (2001) 406-412
29. Nichols B. Caveosomes and endocytosis of lipid rafts. J. Cell Sci. 116 (2003) 4707-4714
30. Schlegel A., and Lisanti M.P. A molecular dissection of caveolin-1 membrane attachment and oligomerization. Two separate regions of the caveolin-1 C-terminal domain mediate membrane binding and oligomer/oligomer interaction in vivo. J. Biol. Chem. 275 (2000) 21605-21617
31. Thomsen P., Roepstorff K., Stahlhut M., and van Deurs B. Caveolae are highly immobile plasma membrane microdomains, which are not involved in constitutive endocytic trafficking. Mol. Biol. Cell 13 (2002) 238-250
32. Fujimoto T., Miyawaki A., and Mikoshiba K. Inositol 1,4,5-trisphosphate receptor-like protein in plasmalemmal caveolae is linked to actin filaments. J. Cell Sci. 108 (1995) 7-15
33. Stahlhut M., and van Deurs B. Identification of filamin as a novel ligand for caveolin-1: evidence for the organization of caveolin-1-associated membrane domains by the actin cytoskeleton. Mol. Biol. Cell 11 (2000) 325-337
34. Parton R.G., Joggerst B., and Simons K. Regulated internalization of caveolae. J. Cell Biol. 127 (1994) 1199-1215
35. Le P.U., Guay G., Altschuler Y., and Nabi I.R. Caveolin-1 is a negative regulator of caveolae-mediated endocytosis to the endoplasmic reticulum. J. Biol. Chem. 277 (2002) 3371-3379
36. Pelkmans L., Kartenbeck J., and Helenius A. Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular transport pathway to the ER. Nat. Cell Biol. 3 (2001) 473-483
37. Pelkmans L., Puntener D., and Helenius A. Local actin polymerization and dynamin recruitment in SV40-induced internalization of caveolae. Science 296 (2002) 535-539
38. Damm E.M., Pelkmans L., Kartenbeck J., Mezzacasa A., Kurzchalia T., and Helenius A. Clathrin-and caveolin-1-independent endocytosis: entry of simian virus 40 into cells devoid of caveolae. J. Cell Biol. 168 (2005) 477-488
39. Torgersen M.L., Skretting G., van Deurs B., and Sandvig K. Internalization of Cholera toxin by different endocytic mechanisms. J. Cell Sci. 114 (2001) 3737-3747
40. Singh R.D., Puri V., Valiyaveettil J.T., Marks D.L., Bittman R., and Pagano R.E. Selective caveolin-1-dependent endocytosis of glycosphingolipids. Mol. Biol. Cell 14 (2003) 3254-3265
41. Nichols B.J. A distinct class of endosomes mediates clathrin-independent endocytosis to the Golgi complex. Nat. Cell Biol. 4 (2002) 374-378
42. Kirkham M., Fujita A., Chadda R., Nixon S.J., Kurzchalia T.V., Sharma D.K., Pagano R.E., Hancock J.F., Mayor S., and Parton R.G. Ultrastructural identification of uncoated caveolin-independent early endocytic vehicles. J. Cell Biol. 168 (2005) 465-476
43. Massol R.H., Larsen J.E., Fujinaga Y., Lencer W.I., and Kirchhausen T. Cholera toxin toxicity does not require functional Arf6-and dynamin-dependent endocytic pathways. Mol. Biol. Cell. 15 (2004) 3631-3641
44. Pang H., Le P.U., and Nabi I.R. Ganglioside GM1 levels are a determinant of the extent of caveolae/raft-dependent endocytosis of Cholera toxin to the Golgi apparatus. J. Cell Sci. 117 (2004) 1421-1430
45. Parton R.G. Ultrastructural localization of gangliosides; GM1 is concentrated in caveolae. J. Histochem. Cytochem. 42 (1994) 155-166
46. Oh P., McIntosh D.P., and Schnitzer J.E. Dynamin at the neck of caveolae mediates their budding to form transport vesicles by GTP-driven fission from the plasma membrane of endothelium. J. Cell Biol. 141 (1998) 101-114
47. Orlandi P.A., and Fishman P.H. Filipin-dependent inhibition of Cholera toxin: evidence for toxin internalization and activation through caveolae like domains. J. Cell Biol. 141 (1998) 905-915
48. Tsai B., Gilbert J.M., Stehle T., Lencer W., Benjamin T.L., and Rapoport T.A. Gangliosides are receptors for murine polyoma virus and SV40. EMBO J. 22 (2003) 4346-4355
49. Lauvrak S.U., Torgersen M.L., and Sandvig K. Efficient endosome-to-Golgi transport of Shiga toxin is dependent on dynamin and clathrin. J. Cell Sci. 117 (2004) 2321-2331
50. Iversen T.G., Skretting G., van Deurs B., and Sandvig K. Formation of clathrin-coated pits with long dynamin-wrapped necks upon inducible expression of antisense clathrin. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 5175-5180
51. Saint-Pol A., Yelamos B., Amessou M., Mills I., Dugast M., Tenza D., Schu P., Antony C., McMahon H.T., Lamaze C., and Johannes L. Clathrin adaptor epsinR is required for retrograde sorting on early endosomal membranes. Dev. Cell 6 (2004) 525-538
52. Mallard F., Tenza D., Antony C., Salamero J., Goud G., and Johannes L. Direct pathway from early/recycling endosomes to the Golgi apparatus revealed through the study of Shiga toxin-B fragment transport. J. Cell Biol. 143 (1998) 973-990
53. Cabiaux V. pH-sensitive toxins: interactions with membrane bilayers and application to drug delivery. Adv. Drug Del. Rev. 56 (2004) 987-997
54. Watson P., and Spooner R.A. Toxin entry and trafficking in mammalian cells. Ad. Drug Del. Rev. 58 (2006) 1581-1596
55. Sandvig K., Garred O., Prydz K., Kozlov J.V., Hansen S.H., and van Deurs B. Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum. Nature 358 (1992) 510-512
56. Schapiro F.B., Lingwood C., Furuya W., and Grinstein S. pH-independent retrograde targeting of glycolipids to the Golgi complex. Am. J. Physiol. 274 (1998) C319-C332
57. Dahms N.M., Lobel P., and Kornfeld S. Mannose 6-phosphate receptors and lysosomal enzyme targeting. J. Biol. Chem. 264 (1989) 12115-12118
58. Lombardi D., Soldati T., Riederer M.A., Goda Y., Zerial M., and Pfeffer S.R. Rab9 functions in transport between late endosomes and trans Golgi network. EMBO J. 12 (1993) 677-682
59. Sandvig K., Grimmer S., Lauvrak S.U., Torgersen M.L., Skretting G., van Deurs B., and Iversen T.G. Pathways followed by Ricin and Shiga toxin into cells. Histochem. Cell Biol. 117 (2002) 131-141
60. Iversen T.G., Skretting G., LLorente A., Nicoziani P., van Deurs B., and Sandvig K. Endosome to Golgi transport of Ricin is independent of clathrin and of the Rab9-Rab11-GTPases. Mol. Biol. Cell 12 (2001) 2099-2107
61. Lauvrak S., Llorente A., Iversen T.G., and Sandvig K. Selective regulation of the Rab9-independent transport of ricin to the Golgi apparatus by calcium. J. Cell Sci. 115 (2002) 3449-3456
62. Wilcke M., Johannes L., Galli T., Mayau V., Goud B., and Salamero J. Rab11 regulates the compartmentalization of early endosomes required for efficient transport from early endosomes to the trans-Golgi network. J. Cell Biol. 151 (2000) 1207-1220
63. Monier S., Jollivet F., Janoueix-Lerosey I., Johannes L., and Goud B. Characterization of novel Rab6-interacting proteins involved in endosome-to-TGN transport. Traffic 3 (2002) 289-297
64. Mallard F., Tang D.B.L., Galli T., Tenza D., Saint-Pol A., Yue X., Antony C., Hong W.J., Goud B., and Johannes L. Early/recycling endosomes-to-TGN transport involves two SNARE complexes and a Rab6 isoform. J. Cell Biol. 156 (2002) 653-664
65. Amessou M., Fradagrada A., Falguieres T., Lord J.M., Smith D.C., Roberts L.M., Lamaze C., and Johannes L. Syntaxin 16 and syntaxin 5 are required for efficient retrograde transport of several exogenous and endogenous cargo proteins. J. Cell Sci. 120 (2007) 1457-1468
66. Falguieres T., Mallard F., Baron C., Hanau D., Lingwood C., Goud B., Salamero J., and Johannes L. Targeting of Shiga toxin B-subunit to retrograde transport route in association with detergent-resistant membranes. Mol. Biol. Cell 12 (2001) 2453-2468
67. Tai G., Lu L., Wang T.L., Tang B.L., Goud B., Johannes L., and Hong W. Participation of the syntaxin 5/Ykt6/GS28/GS15 SNARE complex in transport from early/recycling endosome to the trans-Golgi network. Mol. Biol. Cell 15 (2004) 4011-4022
68. Storrie B. Maintenance of Golgi apparatus structure in the face of continuous protein recycling to the endoplasmic reticulum: making ends meet. Int. Rev. Cytol. 244 (2005) 69-94
69. Marsh B.J., and Howell K.E. The mammalian Golgi-complex debates. Nature Rev. Mol. Cell Biol. 3 (2002) 789-795
70. Farquhar M.G., and Palade G.E. The Golgi apparatus: 100 years of progress and controversy. Trends Cell Biol. 8 (1998) 2-10
71. van Vliet C., Thomas E.C., Merino-Trigo A., Teasdale R.D., and Gleeson P.A. Intracellular sorting and transport of proteins. Prog. Biophys. Mol. Biol. 83 (2003) 1-45
72. Altan-Bonnet N., Sougrat R., and Lippincott-Schwartz J. Molecular basis for Golgi maintenance and biogenesis. Curr. Op. Cell Biol. 16 (2004) 363-372
73. Johannes L., Tenza D., Antony C., and Goud B. Retrograde transport of KDEL-bearing B-fragment of Shiga Toxin. J. Biol. Chem. 272 (1997) 19554-19561
74. Fujinaga Y., Wolf A.A., Rodighiero C., Wheeler H., Tsai B., Allen L., Jobling M.G., Rapoport T., Holmes R.K., and Lencer W.I. Gangliosides that associate with lipid rafts mediate transport of Cholera and related toxins from the plasma membrane to the endoplasmic reticulum. Mol. Biol. Cell 14 (2003) 4783-4793
75. Hessler J.L., and Kreitman R.J. An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor. Biochemistry 36 (1997) 14577-14582
76. Smith D.C., Spooner R.A., Watson P.D., Murray J.L., Hodge T.W., Amessou M., Johannes L., Lord J.M., and Roberts L.M. Internalized Pseudomonas exotoxin A can exploit multiple pathways to reach the endoplasmic reticulum. Traffic 7 (2006) 379-393
77. Lippincott-Schwartz J., Yuan L., Bonifacino J.S., and Klausner R.D. Rapid redistribution of Golgi proteins into the ER in cells treated with brefeldin A: evidence for membrane cycling from Golgi to ER. Cell 56 (1989) 801-813
78. Sciaky N., Presley J., Smith C., Zaal K.J., Cole N., Moreira J.E., Terasaki M., Siggia E., and Lippincott-Schwartz J. Golgi tubule traffic and the effects of brefeldin A visualized in living cells. J. Cell Biol. 139 (1997) 1137-1155
79. Girod A., Storrie B., Simpson J.C., Johannes L., Goud B., Roberts L.M., Lord J.M., Nilsson T., and Pepperkok R. Evidence for a COP-I-independent transport route from the Golgi complex to the endoplasmic reticulum. Nat. Cell Biol. 1 (1999) 423-430
80. Ward T.H., Polishchuk R.S., Caplan S., Hirschberg K., and Lippincott-Schwartz J. Maintenance of Golgi structure and function depends on the integrity of ER export. J. Cell Biol. 155 (2001) 557-570
81. Puri S., and Linstedt A.D. Capacity of the Golgi apparatus for biogenesis from the endoplasmic reticulum. Mol. Cell Biol. 14 (2003) 5011-5018
82. Storrie B., White J., Rottger S., Stelzer E.H., Suganuma T., and Nilsson T. Recycling of Golgi-resident glycosyltransferases through the ER reveals a novel pathway and provides explanation for nocodazole-induced Golgi scattering. J. Cell Biol. 143 (1998) 1505-1521
83. Miles S., McManus H., Forsten K.F., and Storrie B. Evidence that the entire Golgi apparatus cycles in interphase HeLa cells: sensitivity of Golgi matrix proteins to an ER exit block. J. Cell Biol. 155 (2001) 543-555
84. Rhee S.W., Starr T., Forsten-Williams K., and Storrie B. The steady-state distribution of glycosyltransferases between the Golgi apparatus and the endoplasmic reticulum is approximately 90:10. Traffic 6 (2005) 978-990
85. Seemann J., Jokitalo E., Pypaert M., and Warren G. Matrix proteins can generate the higher order architecture of the Golgi apparatus. Nature 407 (2000) 1022-1026
86. Stroud W.J., Jiang S., Jack G., and Storrie B. Persistence of Golgi matrix distribution exhibits the same dependence on Sar1p activity as a Golgi glycosyltransferase. Traffic 4 (2003) 631-641
87. White J., Johannes L., Mallard F., Girod A., Grill S., Reinsch S., Keller P., Tzschaschel B., Echard A., Goud B., and Stelzer E.H.K. Rab6 coordinates a novel Golgi to ER retrograde transport pathway in live cells. J. Cell Biol. 147 (1999) 743-759
88. Young J., Stauber T., del Nery E., Vernos I., Pepperkok R., and Nilsson T. Regulation of microtubule-dependent recycling at the trans-Golgi network by Rab6A and Rab6A'. Mol. Cell Biol. 16 (2005) 162-177
89. del Nery E., Miserey-Lenkei S., Falguieres T., Nizak C., Johannes L., Perez F., and Goud B. Rab6A and Rab6A' GTPases play non-overlapping roles in membrane trafficking. Traffic 7 (2006) 394-407
90. Jiang S., and Storrie B. Cisternal Rab proteins regulate Golgi apparatus redistribution in response to hypotonic stress. Mol. Cell Biol. 16 (2005) 2586-2596
91. Valsdottir R., Hashimoto H., Ashman K., Koda T., Storrie B., and Nilsson T. Identification of rabaptin-5, rabex-5, and GM130 as putative effectors of Rab33b, a regulator of retrograde traffic between Golgi apparatus and ER. FEBS Lett. 508 (2001) 201-209
92. Schmitz A., Herrgen H., Winkeler A., and Herzog V. Cholera toxin is exported from microsomes by the Sec61p complex. J. Cell Biol. 148 (2000) 1203-1212
93. Slominska-Wojewodzka M., Gregers T.F., Walchli S., and Sandvig K. EDEM is involved in retrotranslocation of Ricin from the endoplasmic reticulum to the cytosol. Mol. Biol. Cell 17 (2006) 1664-1675
94. Ackerman A.L., Giodini A., and Cresswell P. A role for the endoplasmic reticulum protein retrotranslocation machinery during crosspresentation by dendritic cells. Immunity 25 (2006) 607-617
95. Yu M., and Haslam D.B. Shiga toxin is transported from the endoplasmic reticulum following interaction with the luminal chaperone HEDJ/ERdj3. Infect. Immun. 73 (2005) 2524-2532
96. Ghosh R.N., Mallet W.G., Soe T.T., McGraw T.E., and Maxfield F.R. An endocytosed TGN38 chimeric protein is delivered to the TGN after trafficking through the endocytic recycling compartment in CHO cells. J. Cell Biol. 142 (1998) 923-936
97. Mallet W.G., and Maxfield F.R. Chimeric forms of furin and TGN38 are transported from the plasma membrane to the trans-Golgi network via distict endosomal pathways. J. Cell Biol. 146 (1999) 345-359
98. Bachert C., Lee T.H., and Linstedt A.D. Lumenal endosomal and Golgi-retrieval determinants involved in pH-sensitive targeting of and early Golgi protein. Mol. Biol. Cell 12 (2001) 3152-3160
99. Puri S., Bachert C., Fimmel C.J., and Linstedt A.D. Cycling of early Golgi proteins via the cell surface and endosomes upon luminal pH disruption. Traffic 3 (2002) 641-653
100. Natarajan R., and Linstedt A.D. A cycling cis-Golgi protein mediates endosome-to-Golgi traffic. Mol. Biol. Cell 15 (2004) 4798-4806
101. T. Starr, K. Forsten-Williams, B. Storrie, Both post-Golgi and intra-Golgi cycling affect the distribution of the Golgi phosphoprotein GPP130, Traffic, in press, doi:10.1111/j.1600-0854.2007.00607.x.
102. Daugherty A.L., and Mrsny R.J. Formulation and delivery issues for monoclonal antibody therapeutics. Ad. Drug Deliv. Rev. 58 (2006) 686-706
103. Birch J.R., and Racher A.J. Antibody production. Ad. Drug Deliv. Rev. 58 (2006) 671-685
104. Wadia J.S., and Dowdy S.F. Transmembrane delivery of protein peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv. Drug Deliv. Rev. 57 (2005) 579-596
105. Brooks H., Lebleu B., and Vives E. Tat peptide-mediated cellular delivery: back to basics. Adv. Drug Deliv. Rev. 57 (2005) 559-577
106. Chauhan A., Tikoo A., Kapur A.K., and Singh M. The taming of the cell penetrating domain of the HIV Tat: myths and realities. J. Control. Release 117 (2007) 148-162
107. Gosselin M.A., and Lee R.J. Folate receptor-targeted liposomes as vectors for therapeutic agents. Biotech. Annu. Rev. 8 (2002) 103-131
108. Anderson R., Kamen B.A., Rothberg K.G., and Lacey S.W. Potocytosis: sequestration and transport of small molecules by caveolae. Science 255 (1992) 410-411
109. Mayor S., Rothberg K.G., and Maxfield F.R. Sequestration of GPI-anchored proteins in caveolae triggered by cross-linking. Science 264 (1994) 1948-1951
110. Wu M., Fan J., Gunning W., and Ratnam M. Clustering of GPI-anchored folate receptor independent of both cross-linking and association with caveolin. J. Membr. Biol. 159 (1997) 137-147
111. Lee R.J., and Low P.S. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta 1233 (1995) 134-144
112. Lackey C.A., Press O.W., Hoffman A.S., and Stayton P.S. A biomimetic pH-responsive polymer directs endosomal release and intracellular delivery of and endocytosed antibody complex. Bioconjug. Chem. 13 (2002) 936-1001
113. Yessine M.A., and Leroux J.C. Membrane-destabilizing polyanions: interaction with lipid bilayers and endosomal escape of biomacromolecules. Adv. Drug Deliv. Rev. 56 (2004) 999-1021
114. Sandvig K., and van Deurs B. Membrane traffic exploited by protein toxins. Annu. Rev. Cell Dev. Biol. 18 (2002) 1-24
115. Sandvig K., and van Deurs B. Delivery into cells: lessons learned from plant and bacterial toxins. Gene Ther. 12 (2005) 865-872
116. Johannes L., and Decaudin D. Protein toxins: intracellular trafficking for targeted therapy. Gene Ther. 12 (2005) 1360-1368
117. Kreitman R.J. Immunotoxins for targeted cancer therapy. AAPS J. 8 (2006) E532-E551
118. Wiseman G.A., Leigh B., Erwin W.D., Dominick L., Kornmehl E., Spies S.M., Silverman D.H.S., Witzig T.E., Sparks R.B., and White C.A. Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer 94 (2002) 1349-1357
119. Wangler C., Buchmann I., Eisenhut M., Haberkorn U., and Mier W. Radiolabeled peptides and proteins in cancer therapy. Prot. Peptide. Lett. 14 (2007) 273-279
120. Hamann P.R., Hinman L.M., Hollander I., Beyer C.F., Lindh D., Holcomb R., Hallett W., Tsou H.R., Upeslacis J., and Shochat D. Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug. Chem. 13 (2002) 47-58
121. Hamann P.R., Hinman L.M., Beyer C.F., Lindh D., Upeslaci J., Flowers D.A., and Bernstein I. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug. Chem. 13 (2002) 40-46
122. Sievers E.L., and Linenberger M. Mylotarg: antibody-targeted chemotherapy comes of age. Curr. Opin. Oncol. 13 (2001) 522-527
123. Saito G., Swanson J.A., and Lee K.D. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv. Drug Deliv. Rev. 55 (2003) 199-215
124. Mueller B.M., Wrasidlo W.A., and Reisfeld R.A. Antibody conjugates with morpholinodoxorubicin and acid-cleavable linkers. Bioconjug. Chem. 1 (1990) 325-330
125. Duncan R. Designing polymer conjugates as lysosomotropic nanomedicines. Biochem. Soc. Trans. 35 (2007) 56-60
126. Seymour L.W., Ferry D.R., Anderson D., Hesslewood S., Julyan P.J., Poyner R., Doran J., Young A.M., Burtles S., and Kerr D.J. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol. 20 (2002) 1668-1676
127. O'Brien A.D., Tesh V.L., Donohue-Rolfe A., Jackson M.P., Olsnes S., Sandvig K., Lindberg A.A., and Keusch G.T. Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr. Top. Microbiol. Immunol. 182 (1992) 65-94
128. Sandvig K. The Shiga toxins: properties and action on cells. In: Alouf J.E., and Popoff M.R. (Eds). The Comprehensive Sourcebook of Bacterial Protein Toxins. third edition (2006), Academic Press, Paris 310-322
129. Acheson D.W.K., Calderwood S.B., Boyko S.A., Lincicome L.L., Kane A.V., Donohue-Rolfe A., and Keusch G.T. Comparison of Shiga-like toxin I B-subunit expression and localization in Escherichia coli and Vibrio cholerae by using trc or iron-regulated promoter system. Infect. Immun. 61 (19993) 1098-1104
130. Calderwood S.B., Auclair F., Dohanue-Rolfe A., Keusch G.T., and Mekalanos J.J. Nucleotide sequence of the Shiga-like toxin genes of Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 4364-4368
131. Donohue-Rolfe A., Acheson A., Kane A.V., and Keusch G.T. Purification of Shiga and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and the production of cross-reactive monoclonal antibodies. Infect. Immun. 57 (1989) 3888-3893
132. 125I]verotoxin. Biochim. Biophys. Acta 1501 (2000) 116-124
133. 3. Biochemistry 37 (1998) 1777-1788
134. Haicheur N., Bismuth E., Bosset S., Adotevi O., Warnier G., Lacabanne V., Regnault A., Desaymard C., Amiogorena S., Ricciardi-Castagnoli P., Goud B., Fridman W.H., Johannes L., and Tartour E. The B subunit of Shiga toxin fused to a tumor antigen elicits CTL and targets dendritic cells to allow MHC class I-restricted presentation of peptides derived from exogenous antigens. J. Immunol. 165 (2000) 3301-3308
135. + hematopoietic stem cells: implications of ex vivo tumor purging and autologous stem cell transplantation. Blood 94 (1999) 2901-2910
136. Trombetta E.S., and Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu. Rev. Immunol. 23 (2005) 975-1028
137. Smith D.C., Lord J.M., Roberts L.M., Tartour E., and Johannes L. 1st class ticket to class I: protein toxins as pathfinders fro antigen presentation. Traffic 3 (2002) 697-704
138. Lee R.S., Tartour E., van der Bruggen P., Vantomme V., Joyeux I., Goud B., Fridman W.H., and Johannes L. Major histocompatibility complex class I presentation of exogenous soluble tumor antigen fused to the B-fragment of Shiga toxin. Eur. J. Immunol. 28 (1998) 2726-2737
139. h1-dominant polarization. Int. Immunol. 15 (2003) 1161-1171
140. Vingert B., Adotevi O., Patin D., Jung S., Shrikant P., Freyburger L., Eppolito C., Sapoznikov A., Amessou M., Quintin-Colonna F., Fridman W.H., Johannes L., and Tartour E. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. Eur. J. Immunol. 36 (2006) 1124-1135
141. Hakomori S.I. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 10231-10233
142. Ono M., and Hakomori S.I. Glycosylation defining cancer cell motility and invasiveness. Glycoconj. J. 20 (2004) 71-78
143. 3) expression in human tumor cells: intracellular trafficking defines a new retrograde transport pathway from the cell surface to the nucleus, which correlates with sensitivity to Verotoxin. Acta Biochim. Pol. 45 (1998) 351-359
144. Farkas-Himsley H., Hill R., Rosen B., Arab S., and Lingwood C.A. The bacterial colicin active against tumor cells in vitro and in vivo is Verotoxin 1. Proc. Natl. Sci. U. S. A. 92 (1995) 6996-7000
145. Arab S., Russel E., Chapman W.B., Rosen B., and Lingwood C.A. Expression of the Verotoxin receptor glycolipid globotriaosylceramide, in ovarian hyperplasias. Oncol. Res. 9 (1997) 553-563
146. LaCasse E.C., Saleh M.T., Patterson B., Minden M.D., and Gariepy J. Shiga-like toxin purges human lymphoma from bone marrow of severe combined immunodeficient mice. Blood 88 (1996) 1561-1567
147. Arab S., Murakami M., Dirks P., Boyd B., Habbard S.L., Lingwood C.A., and Rutka J.T. Verotoxins inhibit the growth of and induce apoptosis in human astrocytoma cells. J. Neuro-Oncol. 40 (1998) 137-150
148. Salhia B., Rutka J.T., Lingwood C., Nutikka A., and Van Furth W.R. The treatment of malignant meningioma with Verotoxin. Neoplasia 4 (2002) 304-311
149. Kovbasnjuk O., Mourtazina R., Baibakov B., Wang T., Elowsky C., Choti M.A., Kane A., and Donowitz M. The glycosphingolipid globotriaosylceramide in metastatic transformation of colon cancer. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 19087-19092
150. Ohyama C., Fukushi Y., Satoh M., Saitoh S., Orikasa S., Nudelman E., Straud M., and Hakomori S. Changes in glycolipid expression in human testicular tumor. Int. J. Cancer 45 (1990) 1040-1044
151. Ohyama C., Orikasa S., Satoh M., Saito S., Ohtani H., and Fukushi Y. Globotriaosyl ceramide glycolipid in seminoma: its clinicopathological importance in differentiation from testicular malignant lymphoma. J. Urol. 148 (1992) 72-75
152. Lingwood C.A. Glycolipid receptors for Verotoxin and Helicobacter pylori: role in pathology. Biochim. Biophys. Acta 1455 (1999) 375-386
153. Hughes A.K., Ergonul Z., Stricklett P.K., and Kohan D.E. Molecular basis for high renal cell sensitivity to the cytotoxic effects of Shigatoxin-1: upregulation of globotriaosylceramide expression. J. Am. Soc. Nephrol. 13 (2002) 2239-2245
154. Ohmi K., Kiyokawa N., Takeda T., and Fujimoto J. Human microvascular endothelial cells are strongly sensitive to Shiga toxins. Biochem. Biophys. Res. Comm. 251 (1998) 137-141
155. 3. J. Infect. Dis. 166 (1992) 832-836
156. Arbus G.S., Grisaru S., Segal O., Dosch M., Pop M., Lala P., Nutikka A., and Lingwood C.A. Verotoxin targets lymphoma infiltrates of patients with post-transplant lymphoproliferative disease. Leuk. Res. 24 (2000) 857-864
157. Butch A.W., and Nahm M.H. Functional properties of human germinal center B cells. Cell Immunol. 140 (1992) 331-344
158. Bitzan M., Richardson S., Huang C., Boyd B., Petric M., and Kamali M.A. Evidence that Verotoxins (Shiga-like toxins) from Escherichia coli bind to P blood group antigens of human erythrocytes in vitro. Infect. Immun. 62 (1994) 3337-3347
159. Heath-Engel H.M., and Lingwood C.A. Verotoxin sensitivity of ECV304 cells in vitro and in vivo in xenograft tumor model: VT1 as a tumor neovascular marker. Agiogenesis 6 (2003) 129-141
160. Tarragó-Trani M.T., Jiang S., Harich K.C., and Storrie B. Shiga-like toxin subunit B (SLTB)-enhanced delivery of Chlorin e6 (Ce6) improves cell killing. Photochem. Photobiol. 82 (2006) 527-537
161. Hicks S., and Machamer C.E. Golgi structure in stress sensing and apoptosis. Biochim. Biophys. Acta 1744 (2005) 406-414
162. B. Storrie, M.T. Tarragó-Trani, S. English, B/B-like fragment targeting for the purposes of photodynamic therapy and medical imaging, United States Patent 6,631,283 (2003).
163. Jansen K.P., Vignjevic D., Boisgard R., Falguieres T., Bousquet G., Decaudin D., Dolle F., Louvard D., Tavitian B., Robine S., and Johannes L. In vivo tumor targeting using a novel intestinal pathogen-based delivery approach. Cancer Res. 66 (2006) 7230-7236